Search clinical trials for: JNJ-42756493: Part 1

Total 458 results

Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma

Tumor or Lymphoma

United States, France, Spain
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma

Neoplasms | Lymphoma | Adenocarcinoma | Esophagogastric Junction

Japan
Janssen Research & Development, LLC

Completed

Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

Healthy

Belgium
Janssen Cilag N.V./S.A.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets

Healthy

Belgium
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib

Hepatic Impairment

Germany
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)

Advanced Solid Tumor

France, United States, Japan, Belgium, United Kingdom, Germany, Korea, Republic of, Taiwan, China, Poland, Italy, Spain, Australia, Brazil, Argentina
Janssen Research & Development, LLC

Completed

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

Healthy

United States
Janssen Scientific Affairs, LLC

Approved for marketing

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Advanced Cancers and FGFR Genetic Alterations
M.D. Anderson Cancer Center

Active, not recruiting

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma | Castration-Resistant...

United States
Lung Cancer Group Cologne

Terminated

FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)

NSCLC | Lung Cancer | NSCLC Stage IV | Squamous Cell Lung Cancer | Pulmonary Neoplasm

Germany
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment | Prodromal Alzheimer's Disease
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Neoplasm

China, Taiwan, Korea, Republic of
Janssen Research & Development, LLC

Completed

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China, Taiwan, Korea, Republic of
Janssen Pharmaceutical K.K.

Recruiting

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer (TAR-210)

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Japan
Janssen Research & Development, LLC

Recruiting

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Korea, Republic of, United States, Germany, Spain, Netherlands
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Urothelial Carcinoma

France, United States, Korea, Republic of, Belgium, Taiwan, Turkey, Russian Federation, Spain, Italy, United Kingdom, Brazil, Belarus, Poland
Novartis Pharmaceuticals

Completed

A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients

Primary Biliary Cholangitis

United States, Germany, Russian Federation, Canada, United Kingdom, Poland
Pfizer

Completed

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

Rheumatoid Arthritis | Healthy Volunteers

United States
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Completed

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects (CHF6333 FIH)

Cystic Fibrosis | Non-Cystic Fibrosis Bronchiectasis

Belgium
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis

Healthy | Asthma | Atopic Dermatitis

Germany, Belgium
Akesobio Australia Pty Ltd

Completed

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Atopic Dermatitis

New Zealand, Australia
Children's Hospital of Philadelphia
Agency for Healthcare Research and Quality (AHRQ)

Completed

Improving Otitis Media Care With Clinical Decision Support (OMHIT)

Otitis Media

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

CD20-positive B-cell Non-Hodgkin Lymphoma

United States, France
Sun Pharma Advanced Research Company Limited

Terminated

A Study in Patients With Advanced Breast Cancer

Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer

United States, India
Chiesi Farmaceutici S.p.A.

Terminated

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD (CHF6297 FIH)

Chronic Obstructive Pulmonary Disease

United Kingdom
UCB Pharma
Parexel

Completed

Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject

Psoriasis

United Kingdom
Tetherex Pharmaceuticals Corporation

Completed

Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)

Chronic Obstructive Pulmonary Disease | Asthma

United Kingdom
AstraZeneca
Acerta Pharma, LLC

Completed

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

Bioavailability | B-cell Lymphoid Cancer

United States
Huahui Health

Completed

A Study to Evaluate the Safety and Pharmacokinetics of HH-120 Nasal Spray in Healthy Volunteers

COVID-19

China
Wake Forest University Health Sciences

Completed

Social Determinants of Health in Glioblastoma Population

Glioma | Astrocytoma | Ependymoma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Oligodendroglioma

United States
Daewoong Pharmaceutical Co. LTD.

Terminated

Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo

Mild to Moderate COVID-19

Korea, Republic of
Axalbion SA

Completed

AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects

Healthy

United Kingdom
Bilix Co.,Ltd.

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants

Ischemia-reperfusion Injury

Australia
GlaxoSmithKline

Withdrawn

A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Cancer

Australia
Bukwang Pharmaceutical

Active, not recruiting

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components (SHINE)

Parkinson Disease | Dyskinesias

United States
Bilthoven Biologicals
Serum Institute of India Pvt. Ltd.

Completed

A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals

Immune Response to Oral Polio Vaccine

Bangladesh
iN Therapeutics Co., Ltd.

Recruiting

A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.

Pain | Osteoarthritis | Chronic Pain | Neuropathic Pain | Post Herpetic Neuralgia

Australia
Kanyos Bio, Inc., a wholly-owned subsidiary of...
Pfizer

Recruiting

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

Celiac Disease

United States, Australia, New Zealand
M.D. Anderson Cancer Center

Terminated

Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems

Skin Cancer

United States
Elpiscience Biopharma, Ltd.

Active, not recruiting

A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumor

United States
Actimed Therapeutics Ltd
Quotient Sciences

Completed

Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV)

Cachexia

United Kingdom
Cellid Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine

COVID-19 | Vaccines

Korea, Republic of
Bausch & Lomb Incorporated

Completed

Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)

Anaphylaxis

Germany
Hvivo
Pfizer

Recruiting

Dose, Safety, and Pathogenicity of a New Influenza B Strain

Influenza B

United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients

Small Cell Lung Cancer

China
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)

Non-Muscle Invasive Bladder Cancer

United States, Israel
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Volunteers

Healthy

United Kingdom

3

Subscribe